Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma Androgen Receptor in Prostate Cancer.
Conteduca V, Gurioli G, Brighi N, Lolli C, Schepisi G, Casadei C, Burgio SL, Gargiulo S, Ravaglia G, Rossi L, Altavilla A, Farolfi A, Menna C, Colangione SP, Pulvirenti M, Romeo A, De Giorgi U. Conteduca V, et al. Among authors: menna c. Cancers (Basel). 2019 Nov 4;11(11):1719. doi: 10.3390/cancers11111719. Cancers (Basel). 2019. PMID: 31689899 Free PMC article. Review.
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U. Conteduca V, et al. Among authors: menna c. Sci Rep. 2018 Oct 18;8(1):15442. doi: 10.1038/s41598-018-33774-4. Sci Rep. 2018. PMID: 30337589 Free PMC article.
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U. Altavilla A, et al. Among authors: menna c. Expert Opin Pharmacother. 2020 Dec;21(17):2091-2099. doi: 10.1080/14656566.2020.1803281. Epub 2020 Aug 12. Expert Opin Pharmacother. 2020. PMID: 32783772 Review.
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, Calistri D, Attard G, De Giorgi U. Salvi S, et al. Among authors: menna c. Br J Cancer. 2015 May 12;112(10):1717-24. doi: 10.1038/bjc.2015.128. Epub 2015 Apr 21. Br J Cancer. 2015. PMID: 25897673 Free PMC article.
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Conteduca V, Scarpi E, Caroli P, Salvi S, Lolli C, Burgio SL, Menna C, Schepisi G, Testoni S, Gurioli G, Paganelli G, Casadio V, Matteucci F, De Giorgi U. Conteduca V, et al. Among authors: menna c. Sci Rep. 2017 Nov 14;7(1):15541. doi: 10.1038/s41598-017-15928-y. Sci Rep. 2017. PMID: 29138500 Free PMC article.
131 results